Table 1.

Clinical characteristics of 84 patients used in the independent validation study by qRT-PCR

Clinical variableHCC samples (N = 58)
Adjacent noncancerous hepatic samples (n = 10)
Other cirrhosis samples (n = 26)
n (%)Rangen (%)Rangen (%)Range
Sex
    Male52 (89.7)10 (100)7 (26.9)
    Female6 (10.4)0 (0)18 (69.2)
    Unknown0 (0)0 (0)1 (3.9)
Age (y)
    <5020 (34.5)33-496 (60)33-498 (30.8)19-48
    ≥5038 (65.5)50-744 (40)57-7418 (69.2)50-68
Hepatitis viral infection
    HBV+58 (100)10 (100)0 (0)
    HBV and HCV+1 (17)1 (10)0 (0)
HBV infection status
    AVR-CC14 (24.1)2 (20)0 (0)
    CC44 (75.9)8 (80)0 (0)
Cirrhosis (pathologic)
    Yes55 (94.8)10 (100)26 (100)
    No3 (5.2)0 (0)0 (0)
Child-Pugh staging
    A52 (94.5)10 (100)0 (0)
    B3 (5.5)0 (0)13 (50)
    C0 (0)0 (0)10 (38.5)
    Unknown0 (0)0 (0)3 (11.5)
AFP (ng/mL)
    <2050 (86.2)1-188 (80)3-8NA
    ≥3008 (13.8)329-4,6202 (20)329-1,794NA
Tumor size (cm)
    <320 (34.5)1-35 (50)2-3NA
    3-520 (34.5)3-53 (30)3-4NA
    >518 (31.0)5-152 (20)7-8NA
Tumor-node-metastasis staging
    I25 (43.1)4 (40)NA
    II22 (37.9)5 (50)NA
    III10 (17.3)1 (10)NA
    IV1 (1.7)0 (0)NA
  • NOTE: A total of 58 HCC samples, 10 randomly selected adjacent noncancerous and cirrhotic hepatic tissues from these 58 HCC samples, and 26 other cirrhosis liver samples from noncancer patients was used for cross-validation analysis by qRT-PCR. The etiologies of the 26 other cirrhosis cases are autoimmune hepatitis (n = 7), primary biliary cirrhosis (n = 15), and alcoholic liver disease (n = 4).

    Abbreviation: NA, not available.